Abstract
Possibly. Long-acting β-2 agonists (LABAs) used in combination with inhaled corticosteroids (ICS) don't appear to increase all-cause mortality or serious adverse events in patients with persistent asthma compared with ICS alone. Studies showing an increase in catastrophic events had serious methodologic issues. A large surveillance study is ongoing.
MeSH terms
-
Administration, Inhalation
-
Adrenergic beta-2 Receptor Agonists / adverse effects
-
Adrenergic beta-2 Receptor Agonists / therapeutic use*
-
Albuterol / adverse effects
-
Albuterol / analogs & derivatives
-
Albuterol / therapeutic use
-
Asthma / drug therapy*
-
Asthma / mortality
-
Bronchodilator Agents / adverse effects
-
Bronchodilator Agents / therapeutic use*
-
Drug Therapy, Combination
-
Glucocorticoids / administration & dosage*
-
Humans
-
Meta-Analysis as Topic
-
Salmeterol Xinafoate
Substances
-
Adrenergic beta-2 Receptor Agonists
-
Bronchodilator Agents
-
Glucocorticoids
-
Salmeterol Xinafoate
-
Albuterol